Overview
- Kenvue shareholders will receive $3.50 in cash plus 0.14625 Kimberly‑Clark shares per Kenvue share, implying $21.01 per share based on the Oct. 31 close.
- Following closing, Kimberly‑Clark investors are expected to own about 54% of the combined company and Kenvue investors about 46%, with Mike Hsu serving as chairman and CEO and three Kenvue directors joining the board.
- The companies project roughly $32 billion in 2025 revenue and identify about $1.9 billion in cost savings over the first three years after completion.
- The transaction, unanimously approved by both boards, is slated to close in the second half of 2026 pending shareholder approvals and customary conditions.
- Shares moved sharply after the announcement, with Kimberly‑Clark falling roughly 12%–15% premarket as Kenvue rose about 16%–20%, while legal and political scrutiny of Tylenol remains a key risk.